Discontinued — last reported Q2 '18
An increase suggests higher utilization of manufacturing assets and potential diversification of revenue, while a decrease may indicate a strategic shift toward focusing on proprietary product production or a loss of third-party contracts.
This metric represents the total revenue generated from manufacturing animal health products on behalf of third-party ph...
Comparable to contract manufacturing or CDMO revenue lines found in other life sciences and pharmaceutical companies that leverage excess capacity for third-party production.
zts_segment_contract_manufacturing_revenues